| REVIEW ARTICLE |
|
| Year : 2013 | Volume
: 5
| Issue : 2 | Page : 78-82 |
|
|
Bisphosphonate-related osteonecrosis of the jaw: An insight
Shalini Kapoor1, Geetanjali Sikka1, Pallak Arora2, Pradeep Chaudhary3
1 Department of Periodontology, Sri Gobind Tricentenary Dental College, Gurgaon, Haryana, India
2 Department of Oral Medicine and Radiology, Kalka Dental College, Meerut, Uttar Pradesh, India
3 Rajasthan Dental College, Jaipur, Rajasthan, India
Correspondence Address:
Geetanjali Sikka
Department of Periodontology, Sri Gobind Tricentenary Dental College, Gurgaon - 123 505, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0975-8844.124248
|
|
|
Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. They are effective in multiple clinical settings including postmenopausal osteoporosis, low bone mass in men, and drug-induced bone loss. Bisphosphonate-associated osteonecrosis of jaws (BRONJ) may result in serious oral complications, such as osteomyelitis and chronic exposure of necrotic bone. Dentists must be familiar with this disorder and pay special attention to all patients on bisphosphonate therapy due to their defective osteoclast function and reduced osseous tissue vascularity, leading to impaired wound healing and progressive necrosis of jaw bones. The purpose of this article is to review the history and pathogenesis of BRONJ, provide guidance to dentists on possible measures to prevent and manage patients with BRONJ. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
